Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
T-cell Non-Hodgkin LymphomaLymphoma, Extranodal NK-T-Cell
Interventions
DRUG

Busulfan

intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)

DRUG

Fludarabine

intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)

Trial Locations (2)

602-713

RECRUITING

Dong-A University, Busan

700-712

RECRUITING

Keimyung University Dongsan Medical Center, Daegu

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Keimyung University Dongsan Medical Center

OTHER